Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.
Adult
Aged
Betacoronavirus
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
COVID-19
China
/ epidemiology
Comorbidity
Coronavirus Infections
/ blood
Cytokine Release Syndrome
/ etiology
Cytokines
/ blood
Female
Flow Cytometry
Humans
Leukocyte Count
Lymphocyte Count
Lymphocyte Subsets
/ immunology
Lymphopenia
/ etiology
Male
Middle Aged
Neutrophils
/ immunology
Pandemics
Pneumonia, Viral
/ blood
Prognosis
SARS-CoV-2
Time Factors
COVID-19
Coronavirus
Inflammatory cytokine
Lymphopenia
SARS-CoV-2
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
02
2020
revised:
05
04
2020
accepted:
06
04
2020
pubmed:
4
5
2020
medline:
30
5
2020
entrez:
4
5
2020
Statut:
ppublish
Résumé
The dynamic changes of lymphocyte subsets and cytokines profiles of patients with novel coronavirus disease (COVID-19) and their correlation with the disease severity remain unclear. Peripheral blood samples were longitudinally collected from 40 confirmed COVID-19 patients and examined for lymphocyte subsets by flow cytometry and cytokine profiles by specific immunoassays. Of the 40 COVID-19 patients enrolled, 13 severe cases showed significant and sustained decreases in lymphocyte counts [0·6 (0·6-0·8)] but increases in neutrophil counts [4·7 (3·6-5·8)] than 27 mild cases [1.1 (0·8-1·4); 2·0 (1·5-2·9)]. Further analysis demonstrated significant decreases in the counts of T cells, especially CD8 The degree of lymphopenia and a proinflammatory cytokine storm is higher in severe COVID-19 patients than in mild cases, and is associated with the disease severity. N8R and NLR may serve as a useful prognostic factor for early identification of severe COVID-19 cases. The National Natural Science Foundation of China, the National Science and Technology Major Project, the Health Commission of Hubei Province, Huazhong University of Science and Technology, and the Medical Faculty of the University of Duisburg-Essen and Stiftung Universitaetsmedizin, Hospital Essen, Germany.
Sections du résumé
BACKGROUND
BACKGROUND
The dynamic changes of lymphocyte subsets and cytokines profiles of patients with novel coronavirus disease (COVID-19) and their correlation with the disease severity remain unclear.
METHODS
METHODS
Peripheral blood samples were longitudinally collected from 40 confirmed COVID-19 patients and examined for lymphocyte subsets by flow cytometry and cytokine profiles by specific immunoassays.
FINDINGS
RESULTS
Of the 40 COVID-19 patients enrolled, 13 severe cases showed significant and sustained decreases in lymphocyte counts [0·6 (0·6-0·8)] but increases in neutrophil counts [4·7 (3·6-5·8)] than 27 mild cases [1.1 (0·8-1·4); 2·0 (1·5-2·9)]. Further analysis demonstrated significant decreases in the counts of T cells, especially CD8
INTERPRETATION
CONCLUSIONS
The degree of lymphopenia and a proinflammatory cytokine storm is higher in severe COVID-19 patients than in mild cases, and is associated with the disease severity. N8R and NLR may serve as a useful prognostic factor for early identification of severe COVID-19 cases.
FUNDING
BACKGROUND
The National Natural Science Foundation of China, the National Science and Technology Major Project, the Health Commission of Hubei Province, Huazhong University of Science and Technology, and the Medical Faculty of the University of Duisburg-Essen and Stiftung Universitaetsmedizin, Hospital Essen, Germany.
Identifiants
pubmed: 32361250
pii: S2352-3964(20)30138-9
doi: 10.1016/j.ebiom.2020.102763
pmc: PMC7165294
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102763Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors disclose no conflicts of interest.
Références
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Infect Dis. 2014 May 1;209(9):1331-42
pubmed: 24065148
Virus Res. 2009 Nov;145(2):260-9
pubmed: 19635508
Nat Med. 2007 Oct;13(10):1248-52
pubmed: 17891146
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
Nat Med. 2007 Oct;13(10):1142-4
pubmed: 17917657
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Virology. 2014 Apr;454-455:197-205
pubmed: 24725946
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Respirology. 2006 Nov;11(6):715-22
pubmed: 17052299
JAMA. 2020 Mar 17;323(11):1092-1093
pubmed: 32031568
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940